NEW YORK and LONDON, September 21, 2015 AAkari Therapeutics (formerly known as Celsus Therapeutics plc) (NASDAQ: AKTX), an emerging growth, …
[Read more...] about Akari Therapeutics Closes $75 Million Private Placement
Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Completion of Acquisition and Formation of Complement C5 Inhibitor Company Akari Therapeutics Plc
NEW YORK and LONDON, September 18, 2015 Celsus Therapeutics Plc (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that, following …
Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce $75 Million Private Placement
NEW YORK and LONDON, August 18, 2015 Celsus Therapeutics Plc (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that Celsus has entered …
Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Agreement to Create Orphan Disease Company Focused on Complement C5 Inhibition
NEW YORK and LONDON, July 13, 2015 Celsus Therapeutics (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that they have entered into a …
Celsus Therapeutics Announces That the Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint
MRX-6 Cream Did Not Demonstrate Separation from Vehicle in Primary Endpoint of Percent Improvement in the Investigator's Global Assessment NEW YORK and …
